000 01328 a2200373 4500
005 20250514231650.0
264 0 _c20050912
008 200509s 0 0 eng d
022 _a0007-0920
024 7 _a10.1038/sj.bjc.6602676
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aMorris, C D
245 0 0 _aSpecific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence.
_h[electronic resource]
260 _bBritish journal of cancer
_cJun 2005
300 _a2148-52 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
650 0 4 _aAnimals
650 0 4 _aAntineoplastic Agents
_xpharmacology
650 0 4 _aClinical Trials as Topic
650 0 4 _aDrug Evaluation, Preclinical
650 0 4 _aEndothelin A Receptor Antagonists
650 0 4 _aEndothelin B Receptor Antagonists
650 0 4 _aEndothelin-1
_xantagonists & inhibitors
650 0 4 _aHumans
650 0 4 _aRadioligand Assay
650 0 4 _aVasoconstriction
_xdrug effects
700 1 _aRose, A
700 1 _aCurwen, J
700 1 _aHughes, A M
700 1 _aWilson, D J
700 1 _aWebb, D J
773 0 _tBritish journal of cancer
_gvol. 92
_gno. 12
_gp. 2148-52
856 4 0 _uhttps://doi.org/10.1038/sj.bjc.6602676
_zAvailable from publisher's website
999 _c15616094
_d15616094